Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Merck (NYSE:MRK) with a Peer Perform ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Even though Merck & Co., Inc.'s ( NYSE:MRK ) recent earnings release was robust, the market didn't seem to notice.

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our Earnings Yield Investor model based on the published strategy ...

MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...

This post was written by Angel Smith MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.

Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...

Kennedy believes that vaccines cause autism and wants to use his perch to carry out further testing.

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

Understand how AppOmni’s comprehensive SSPM platform helped Inversion6 face their SaaS security challenges and gained ...

These four blue chip stocks with dependable, high-yield dividends should continue to deliver regardless of inflation.